US IPOs and Secondary Offerings, IPO Boutique

IPO Boutique

US IPOs and Secondary Offerings

For more than 20 years, we have been providing research, analysis, commentary and ratings on US Equity Capital Markets to institutional investors (US IPOs and Secondary Offerings). Our vast network of contacts across the Equity Capital Markets and attention-to-detail sets us apart from our competitors.

Since 2012, we have achieved a successful hit rating on 89% of Buy-rated IPOs. The collective “Buy” ratings averaged a first trade of 16.3% above issue.Our Neutral Rated Deals averaged just 2% above the issue price at first trade.

Our written research includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

In addition, we provide a high-touch premium desk access which includes analyst access, as well as real time insights on US IPOs as well as secondary offerings.

IPOs and Secondary Offerings

Equity Capital Markets

<ul>
<li>Late-Stage biotech targeting OSA with AD109, an investigational oral therapy, has submitted an NDA following positive Phase 3 results in approximately 1,300 patients.</li>
<li>Addresses an estimated 80 million U.S. adults with obstructive sleep apnea, offering a potential first oral pharmacologic treatment for a large underserved market.</li>
<li>Backed by Morningside Ventures and Sectoral Asset Management, with over $200 million raised to support late-stage development and potential commercialization.</li>
</ul>


Late-Stage biotech targeting OSA with AD109, an investigational oral therapy, has submitted an NDA following positive Phase 3 results in approximately 1,300 patients.
Addresses an estimated 80 million U.S. adults with obstructive sleep apnea, offering a potential first oral pharmacologic treatment for a large underserved market.
Backed by Morningside Ventures and Sectoral Asset Management, with over $200 million raised to support late-stage development and potential commercialization.


Apnimed Inc. (APMD): Peeking at the IPO Prospectus of a Sleep-Related Biopharma

United States

Apnimed, Inc. is a pharmaceutical company. The Company focuses on the discovery, development, and commercialization of oral therapies that address the neurobiology of sleep-related breathing diseases. Apnimed operates in the United States.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Apnimed Inc. (APMD): Peeking at the IPO Prospectus of a Sleep-Related Biopharma

​Biotech company submits NDA for oral therapy targeting obstructive sleep apnea, potentially offering first oral treatment for a large market,...

IPO Boutique

Biotech company submits NDA for oral therapy targeting obstructive sleep apnea, potentially offering first oral treatment for a large market,...